Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Personalized Natural Killer (NK) Cell Therapy in Cord Blood Transplantation (CBT)

    ... a UCB transplant can improve response in participants with MDS, leukemia, lymphoma, or MM. The safety of this treatment and whether NK ... of minimal residual disease by flow cytometry ), secondary leukemia from prior chemotherapy and/or arising from MDS, any ...

    Clinical Trial last updated 06/06/2016 - 10:28am.

  2. Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... of minimal residual disease by flow cytometry ), secondary leukemia from prior chemotherapy and/or arising from MDS, ...

    Clinical Trial last updated 06/06/2016 - 12:58pm.

  3. CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease

    ... versus host disease, to evaluate incidence of primary and secondary graft rejection, to assess event free survival and overall survival, ... myelodysplastic syndromes (MDS) Gender:  ...

    Clinical Trial last updated 06/13/2016 - 2:06pm.

  4. Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia

    ... myelodysplastic syndromes (MDS) Phase:  ... or high risk mutations by FISH eg MLL, FLT-3 + Secondary AML, or A white blood cell count of > 50 x10^9/L ...

    Clinical Trial last updated 06/13/2016 - 3:31pm.

  5. AML Therapy With Irradiated Allogeneic Cells

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... =< 1.5 mg/dl Any organ dysfunction thought to be secondary to disease will be considered separately and the patient will be ...

    Clinical Trial last updated 06/13/2016 - 3:14pm.

  6. Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies (AB-CliniMACs)

    ... myelodysplastic syndromes (MDS) Phase:  ... Leukemias/lymphomas Acute myeloid leukemia, primary or secondary Disease status: remission or <10% bone marrow blasts ...

    Clinical Trial last updated 06/06/2016 - 3:10pm.

  7. Prior allogeneic transplant Karnofsky Performance Score < 70% Active central nervous system (CNS) involvement by malignant cells Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and with progre

    ... myelodysplastic syndromes (MDS) Phase:  ... de novo AML First or subsequent relapse of AML Secondary AML Treatment with institutional standard AML therapy in those ...

    Clinical Trial last updated 06/06/2016 - 2:05pm.

  8. Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelopdysplastic Syndrome

    ... aplastic anemia (SAA) and myelodysplastic syndrome (MDS) are life-threatening bone marrow disorders. For SAA patients, long ... related donor might promote rapid engraftment and reduce TRM secondary to prolonged neutropenia associated with conventional UCBT. This ...

    Clinical Trial last updated 04/25/2016 - 2:18pm.

  9. Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies (AB-CliniMACs)

    ... myelodysplastic syndromes (MDS) Gender:  ... Leukemias/lymphomas Acute myeloid leukemia, primary or secondary Disease status: remission or <10% bone marrow blasts ...

    Clinical Trial last updated 06/03/2016 - 2:45pm.

  10. Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission (QUAZAR AML-001)

    ... of de novo AML (Acute Myeloid Leukemia) or AML secondary to prior myelodysplastic disease or chronic myelomonocytic leukemia ... myelodysplastic syndromes (MDS) Associated Drug(s):  ...

    Clinical Trial last updated 04/29/2016 - 8:39am.